Chelidonine (Benzophenanthridine Alkaloid · Antispasmodic · Biliary Support)

Compound	Chelidonine
Chemical class	Alkaloid — Isoquinoline (Benzophenanthridine)
CAS	476-32-4
Primary source	Chelidonium majus (greater celandine)
Key applications	Antispasmodic, liver/biliary, antiproliferative (research), topical wart/skin
Claim strength	Moderate
Typical form	Celandine extract (standardised to total alkaloids); isolated chelidonine
Buy from Herbuno	Celandine Extract Powder - Chelidonium majus → Celandine Oil Soluble Extract - Chelidonium majus →

Commercial source: Chelidonine is commercially available as a primary alkaloid in Chelidonium majus (greater celandine) extract, supplied in dry powder and oil-soluble extract formats. See sourcing options below. Traditional use: Greater celandine (Chelidonium majus) has been used in European, Chinese (Bai Qu Cai), and Native American traditions for liver and gallbladder disorders, skin conditions (warts, eczema), respiratory complaints, and as an antispasmodic for abdominal cramps. The orange latex of the plant (visible when stems are broken) is rich in benzophenanthridine alkaloids including chelidonine, and has been applied directly to warts as a topical treatment across many cultures. Research trajectory: Chelidonine has documented antispasmodic, choleretic (bile-stimulating), and antiproliferative activities. It has attracted oncology research interest for its mitosis-inhibiting mechanism (tubulin binding). However, the hepatotoxicity risk associated with Chelidonium majus preparations at higher doses is a significant clinical and regulatory concern that formulators must address. See sourcing options below.

---

Evidence for Chelidonine Applications

Antispasmodic and biliary: Chelidonine relaxes smooth muscle of the biliary tract and intestinal smooth muscle via calcium channel antagonism and direct muscle membrane effects. European clinical traditions use Chelidonium preparations for biliary spasm and liver/gallbladder motility support. German Commission E had a positive monograph for Chelidonium for biliary complaints, though this has been revised in light of hepatotoxicity concerns. Claim strength: Moderate.

Antiproliferative (preclinical): Chelidonine inhibits tubulin polymerisation (preventing spindle formation), inducing mitotic arrest and apoptosis in cancer cell lines. This is a mechanism shared with vinca alkaloids (vincristine, vinblastine) and colchicine — established pharmaceutical antimitotics. Preclinical antiproliferative evidence is well-characterised but clinical translation has not been pursued due to the hepatotoxicity barrier. Claim strength: Moderate (mechanism well-characterised; therapeutic development limited by safety concerns).

Topical antiviral (wart treatment): Celandine latex applied topically for wart treatment is a validated traditional application with a supportive clinical evidence base from European phytomedicine. Chelidonine and related alkaloids have cytotoxic activity relevant to HPV-infected epithelial cells at topical concentrations. Claim strength: Moderate (topical use; oral hepatotoxicity concern does not apply to topical application).

---

Dosage & Formulator Specification

Safety-first dosing context: Chelidonium majus oral preparations have been associated with idiosyncratic hepatotoxicity cases, particularly with long-term use or higher doses (>3 mg/day chelidonine equivalent). The HMPC (European Medicines Agency) has issued safety guidance restricting oral Chelidonium preparations to short-term use (maximum 4 weeks) and contraindicated in individuals with liver disease. European Commission E monograph approval for biliary indications has been withdrawn in some national applications. Formulators must account for this regulatory landscape.

For oral biliary/antispasmodic applications where Chelidonium extract is included: limit to doses providing <2.5 mg/day chelidonine, for maximum 4 weeks, with clear contraindication statements for individuals with liver disease. Request alkaloid profile CoA confirming chelidonine content for precise dose management.

Topical application for wart treatment: Chelidonium latex or celandine extract in topical base at application site for 4–8 weeks is a different safety context from oral use — systemic exposure is minimal and hepatotoxicity risk does not apply.

---

Frequently Asked Questions — Chelidonine

Is Chelidonium majus safe for oral supplementation?
With appropriate dose and duration limits, Chelidonium preparations have been used medicinally for centuries and are included in European phytomedicine standards. The hepatotoxicity risk is idiosyncratic (unpredictable individual susceptibility) and appears dose-related, with long-term use (>4 weeks) at higher doses carrying the greatest risk. For short-term oral use at doses providing <2.5 mg/day chelidonine, the risk-benefit in otherwise healthy individuals has historically been considered acceptable for biliary indications. Formulators must include clear duration limits and contraindications for liver disease on any Chelidonum-containing product label.

How does chelidonine’s mechanism compare to colchicine?
Both inhibit tubulin polymerisation and prevent mitotic spindle formation. Colchicine binds to a specific colchicine-binding site on β-tubulin; chelidonine also binds tubulin but with different binding kinetics and somewhat different selectivity across dividing cell types. Colchicine is a pharmaceutical drug used for gout and familial Mediterranean fever; chelidonine is a botanical alkaloid with analogous but distinct pharmacology not developed for pharmaceutical use.

Is topical celandine (Thuja/celandine wart formulas) safe?
Topical celandine preparations for wart treatment have a long safety record with minimal systemic absorption. The hepatotoxicity concern with Chelidonium relates specifically to oral ingestion. Topical celandine extract in standardised wart treatment formulations is considered safe when applied as directed. Avoid application to mucous membranes or broken skin to minimise systemic alkaloid exposure.

Does chelidonine have any immunomodulatory activity?
Chelidonine has documented immunomodulatory effects including NF-κB inhibition and cytokine production modulation in immune cell models. Anti-inflammatory activity is documented alongside the antiproliferative mechanism. However, the hepatotoxicity concern limits its practical use in oral supplement formulations for immunomodulatory positioning.

---

Claim-strength scale – High = multiple human RCTs; Moderate = limited trials or strong preclinical convergence; Emerging = early-stage lab or animal data.

← HerbIQ Compound Index · HerbIQ P02: Extraction · HerbIQ P03: Delivery